As one of the world’s leading biotechnology companies, Amgen’s greatest contribution to society comes from discovering and developing innovative medicines to treat patients suffering from serious illnesses, such as cardiovascular disease and cancer. In undertaking this important work, Amgen makes a positive contribution in numerous other areas—which we share in our 2017 Responsibility Highlights Report.
The 2017 Responsibility Highlights Report outlines how Amgen is further aligning corporate responsibility efforts with respected international frameworks. The report includes Amgen’s Communication on Progress associated with the ten principles of the United Nations Global Compact. Additionally, this report discusses the ways in which Amgen aligns with the U.N.’s Sustainable Development Goals, which call for broad action to promote prosperity while protecting the planet.
Some highlights of Amgen’s corporate responsibility program from 2017 include:
- Alignment with five Sustainable Development Goals
- One hundred percent of staff completing Amgen’s Code of Conduct Training
- Reducing 118,200 metric tons of carbon emissions since 2007, or 28 percent, saving $28 million in operating costs annually
- Expanding the partnership with the Union for International Cancer Control to support the C/CAN 2025: City Cancer Challenge
- The Amgen Foundation extending the Amgen Biotech Experience to students in nine new regions outside of the U.S.
Amgen’s efforts to be a good corporate citizen are being recognized. In 2017, Amgen was included on the Dow Jones Sustainability World and North America Indices for the fourth and fifth year in a row, respectively. The U.S. Environmental Protection Agency honored Amgen scientists with the Green Chemistry Challenge Award. Amgen earned a perfect score on the 2017 Corporate Equality Index, administered by the Human Rights Campaign Foundation, and, in early 2018, Amgen ranked among the top 100 on Forbes magazine’s inaugural list of “America’s Best Employers for Diversity.”
The report includes, among other data, environmental sustainability performance data that have been independently verified by Bureau Veritas North America.
For additional information on Amgen’s reporting and Responsibility, see the Letter to Shareholders and Amgen Inc. Annual Report and Responsibility on Amgen.com.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
For more information, visit www.amgen.com and follow us on www.twitter.com/amgen/.
Jennifer van der Borgt
+1 (805) 447-5597